Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm

Tongji Hospital0 sites10,000 target enrollmentOctober 1, 2022

ConditionsOvarian Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Ovarian Cancer
Sponsor: Tongji Hospital
Enrollment: 10000
Primary Endpoint: diagnostic accuracy
Status: Not yet recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Ovarian cancer is relatively rare but fatal with an annual incidence rate of 11.8 per 100 000 and a high mortality-to-incidence ratio of >0.6. The modest diagnostic accuracy of TVU has risen some concerns about the over-treatment.Now, with the development of artificial intelligence (AI), we may have a better chance to interpret TVU imagines with high efficiency, reproducibility and accuracy.

Registry

clinicaltrials.gov

Start Date

October 1, 2022

End Date

October 1, 2024

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

Tongji Hospital

Responsible Party

Principal Investigator

Qinglei Gao

Clinical Professor

Tongji Hospital

Eligibility Criteria

Inclusion Criteria

•Women scheduled for Transvaginal Ultrasound examination for adnexal lesions;
•Women aged over 18 years old;
•Women willing to participant in this study evidenced by signing the informed consent.

Exclusion Criteria

•Women without adnexa for any reasons at the time of Transvaginal Ultrasound examination, including but not limited to receiving surgical removal for adnexa;
•Women with a pathologic diagnosis of ovarian cancer before the Transvaginal Ultrasound examination;
•Women with mental abnormal;
•Women did not cooperate or participate in other clinical trials;
•Pregnant or lactating women.